For this purpose we correlated iATP vs. total CD4+ cell counts in n = 286 samples - apart from patients with opportunistic infections - consisting of healthy controls, MS patients devoid of immunomodulatory therapies and MS patients with natalizumab treatment. The gene discussed is CD4; the disease is myeloid sarcoma.